XML 77 R57.htm IDEA: XBRL DOCUMENT v3.3.1.900
ALLIANCES (AstraZeneca) (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Alliances Statement [Line Items]                                
Number of agreements in alliance 3                       3      
The percentage of capital expenditures to be reimbursed by AstraZeneca         50.00%                 50.00%    
Net product sales                         $ 14,045 $ 11,660 $ 12,304  
Alliance revenues                         2,515 4,219 4,081  
Total Revenues $ 4,287 $ 4,069 $ 4,163 $ 4,041 $ 4,258 $ 3,921 $ 3,889 $ 3,811         16,560 15,879 16,385  
Deferred income - Cash flow                         218 613 965  
Divestiture and other proceeds                         708 3,585 9  
Deferred income 1,589       1,937               1,589 1,937    
AstraZeneca [Member]                                
Alliances Statement [Line Items]                                
Annual limit on development agreement costs in 2016                         115      
Proceeds received at closing for sale of business         2,700                 2,700    
Total contingent regulatory and sales based milestone payments         1,400                 1,400    
Contingent approval milestones         800                 800    
Total contingent sales based milestones         600                 600    
Contingent payments related to transfer of certain assets and businesses         225                 225    
Business sale total consideration received                         179 3,800    
Contingent regulatory milestone consideration received                           700    
Portion of proceeds allocated to the sale of business                           3,300    
Portion of proceeds allocated to undelivered elements                           492    
Total earned royalties                           235    
Allocation of goodwill to disposal group                           600    
Reversal of deferred tax liabilities attributed to inside tax basis of disposal group                           821    
Net product sales                         14 160 1,658  
Alliance revenues                         182 135 16  
Total Revenues                         196 295 1,674  
Cost of products sold - Profit sharing                         1 79 673  
Cost of products sold - Amortization of deferred income                             (307)  
Payments to/(from) alliance partner - Cost of products sold                           (9) (25)  
Payments to/(from) alliance partner - Marketing, selling and administrative                           (8) (172)  
Payments to/(from) alliance partner - Research and development                           (16) (86)  
Other (income)/expense - Amortization of deferred income                         (105) (80) (31)  
Provision for restructuring                           (2) (25)  
Royalties                         (215) (192)    
Transitional services                         (12) (90)    
Gain on sale of business   $ 79       $ 292             (82) (536)    
Deferred income - Cash flow                         34 315 215  
Divestiture and other proceeds                         374 3,495    
AstraZeneca [Member] | Amylin Acquisition [Member]                                
Alliances Statement [Line Items]                                
Payment made by an alliance partner to enter into an alliance agreement                               $ 3,600
Payment made by an alliance partner to establish equal governance rights over certain key strategic and financial decisions regarding the alliance                             $ 135  
Useful life of property, plant and equipment                             15 years  
AstraZeneca [Member] | Assets Not Yet Transferred to Alliance Partner [Member]                                
Alliances Statement [Line Items]                                
Deferred income         176                 176    
AstraZeneca [Member] | Services Not Yet Performed For Alliance Partner [Member]                                
Alliances Statement [Line Items]                                
Deferred income 144       $ 226               144 $ 226    
AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                                
Alliances Statement [Line Items]                                
Royalty rate sales threshold - Minimum 500                       500      
Royalty rate sales threshold - Maximum $ 500                       $ 500      
AstraZeneca [Member] | Onglyza Kombiglyze [Member] | Upfront, milestone and other licensing payments [Member]                                
Alliances Statement [Line Items]                                
Total upfront, milestone and other licensing payments received to date                             $ 300  
AstraZeneca [Member] | Amylin Related Products [Member]                                
Alliances Statement [Line Items]                                
Royalty rate on net sales                   10.00% 5.00% 2.00% 2.00%      
Percentage of potential future royalties transferred                         70.00%      
AstraZeneca [Member] | Farxiga [Member] | Upfront, milestone and other licensing payments [Member]                                
Alliances Statement [Line Items]                                
Total upfront, milestone and other licensing payments received to date                             $ 250  
AstraZeneca [Member] | Bydureon [Member]                                
Alliances Statement [Line Items]                                
Useful life of intangible asset                             13 years  
AstraZeneca [Member] | Byetta [Member]                                
Alliances Statement [Line Items]                                
Useful life of intangible asset                             7 years  
AstraZeneca [Member] | Symlin [Member]                                
Alliances Statement [Line Items]                                
Useful life of intangible asset                             9 years  
AstraZeneca [Member] | Myalept [Member]                                
Alliances Statement [Line Items]                                
Useful life of intangible asset                             12 years  
Maximum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                                
Alliances Statement [Line Items]                                
Royalty rate on net sales                 25.00% 20.00% 12.00% 27.00% 35.00% 44.00%    
Maximum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                                
Alliances Statement [Line Items]                                
Royalty rate on net sales                 12.00%              
Minimum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                                
Alliances Statement [Line Items]                                
Royalty rate on net sales                 14.00% 20.00% 12.00% 9.00% 7.00% 3.00%    
Minimum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                                
Alliances Statement [Line Items]                                
Royalty rate on net sales                 5.00%